Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LTRN Stock Forecast 2026-2027
$2.91
Current Price
$37.13M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to LTRN Price Targets
+759.1%
To High Target of $25.00
+587.3%
To Median Target of $20.00
+415.5%
To Low Target of $15.00
LTRN Price Momentum
-19.2%
1 Week Change
-25.2%
1 Month Change
-32.0%
1 Year Change
-4.0%
Year-to-Date Change
-49.3%
From 52W High of $5.74
+162.2%
From 52W Low of $1.11
📊 TOP ANALYST CALLS
Did LTRN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Lantern Pharma is one of their latest high-conviction picks.
Latest LTRN Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, LTRN has a bullish consensus with a median price target of $20.00 (ranging from $15.00 to $25.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $2.91, the median forecast implies a 587.3% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Chad Messer at Lake Street, projecting a 759.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LTRN Analyst Ratings
2
Buy
0
Hold
0
Sell
LTRN Price Target Range
Low
$15.00
Average
$20.00
High
$25.00
Current: $2.91
Latest LTRN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LTRN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 2, 2025 | Lake Street | Chad Messer | Buy | Initiates | $25.00 |
| Apr 25, 2024 | HC Wainwright & Co. | Neutral | Reiterates | $N/A | |
| Aug 10, 2023 | EF Hutton | Buy | Reiterates | $N/A | |
| Jun 26, 2023 | EF Hutton | Buy | Maintains | $N/A | |
| May 25, 2023 | EF Hutton | Michael King | Buy | Assumes | $11.00 |
| May 18, 2023 | HC Wainwright & Co. | Neutral | Initiates | $N/A | |
| Mar 21, 2023 | EF Hutton | Buy | Reiterates | $N/A | |
| Feb 15, 2023 | EF Hutton | Buy | Maintains | $N/A | |
| Nov 1, 2022 | EF Hutton | Buy | Initiates | $N/A | |
| Mar 11, 2022 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 2, 2021 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 7, 2021 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Jul 28, 2020 | Colliers Securities | Buy | Initiates | $N/A |
Lantern Pharma Inc. (LTRN) Competitors
The following stocks are similar to Lantern Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
LTRN
Lantern Pharma
mkt cap
45.93M
Lantern Pharma Inc. (LTRN) Financial Data
Lantern Pharma Inc. has a market capitalization of $37.13M with a P/E ratio of -1.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -157.4%.
Valuation Metrics
Market Cap
$37.13M
Enterprise Value
$28.78M
P/E Ratio
-1.9x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+19.2%
Current Ratio
1.9x
Debt/Equity
1.7x
ROE
-157.4%
ROA
-73.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lantern Pharma Inc. (LTRN) Business Model
About Lantern Pharma Inc.
What They Do
Develops AI-driven oncology therapies.
Business Model
Lantern Pharma generates revenue by advancing its oncology drug candidates through clinical trials, leveraging its proprietary RADR platform to enhance drug discovery and development efficiency. The company focuses on identifying biomarkers and predicting drug responses to effectively stratify patients, which helps in optimizing clinical trial outcomes and targeting specific cancer types with high unmet medical needs.
Additional Information
Founded in 2013 and based in Dallas, Texas, Lantern Pharma utilizes advanced machine learning and genomics to transform traditional drug development processes, with a pipeline that includes several promising candidates in various stages of clinical trials for different cancer indications.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
16
CEO
Mr. Panna Sharma
Country
United States
IPO Year
2020
Website
www.lanternpharma.comLantern Pharma Inc. (LTRN) Latest News & Analysis
Latest News
Quick Summary
Lantern Pharma Inc. (NASDAQ: LTRN) launched ZetaOmics, an AI-driven computational biology module for bioinformatics analysis targeting rare and pediatric cancers.
Why It Matters
Lantern Pharma's launch of ZetaOmics enhances its AI capabilities in oncology, potentially accelerating drug development for rare cancers, which could drive future revenue and market interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Harmonic has announced a presentation in the form of 8K, according to a recent report from Dallas.
Why It Matters
The Harmonic Presentation in 8K signals advancements in video technology, potentially enhancing product offerings and market competitiveness, impacting stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Lantern Pharma Inc. (NASDAQ: LTRN) received a positive response from the FDA regarding its Type C meeting request for the Phase 2 HARMONIC™ trial of LP-300 in advanced NSCLC adenocarcinoma.
Why It Matters
FDA's positive feedback on Lantern Pharma's trial could accelerate LP-300's development, enhancing its market potential and boosting investor confidence in the company's future.
Source: Business Wire
Market Sentiment:
Neutral
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
2 months ago
Quick Summary
Lantern Pharma has reported its financial results for Q1 2026 and provided updates on its business activities. Further details of the report are available for review.
Why It Matters
Lantern Pharma's Q1 2026 financial results and updates may signal its growth trajectory and financial health, influencing investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Lantern Pharma Inc. has announced a registered direct offering of up to $9.25 million with existing holders and one institutional investor.
Why It Matters
The $9.25 million offering indicates financial support and confidence from existing holders and institutional investors, potentially boosting Lantern Pharma's growth prospects and stock value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Lantern Pharma Inc. has completed a registered direct offering, raising up to $9.25 million from existing holders and one institutional investor.
Why It Matters
Lantern Pharma's $9.25 million offering indicates capital raising efforts, potential growth opportunities, and investor confidence, impacting stock valuation and future funding strategies.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About LTRN Stock
What is Lantern Pharma Inc.'s (LTRN) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Lantern Pharma Inc. (LTRN) has a median price target of $20.00. The highest price target is $25.00 and the lowest is $15.00.
Is LTRN stock a good investment in 2027?
According to current analyst ratings, LTRN has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.91. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LTRN stock?
Wall Street analysts predict LTRN stock could reach $20.00 in the next 12 months. This represents a 587.3% increase from the current price of $2.91. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lantern Pharma Inc.'s business model?
Lantern Pharma generates revenue by advancing its oncology drug candidates through clinical trials, leveraging its proprietary RADR platform to enhance drug discovery and development efficiency. The company focuses on identifying biomarkers and predicting drug responses to effectively stratify patients, which helps in optimizing clinical trial outcomes and targeting specific cancer types with high unmet medical needs.
What is the highest forecasted price for LTRN Lantern Pharma Inc.?
The highest price target for LTRN is $25.00 from Chad Messer at Lake Street, which represents a 759.1% increase from the current price of $2.91.
What is the lowest forecasted price for LTRN Lantern Pharma Inc.?
The lowest price target for LTRN is $15.00 from at , which represents a 415.5% increase from the current price of $2.91.
What is the overall LTRN consensus from analysts for Lantern Pharma Inc.?
The overall analyst consensus for LTRN is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $20.00.
How accurate are LTRN stock price projections?
Stock price projections, including those for Lantern Pharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 6:08 AM UTC